Document is current
Any future updates will be listed below
-
Authors
Bakht, Martin K. http://orcid.org/0000-0001-8803-2485
Yamada, Yasutaka http://orcid.org/0000-0002-0070-1590
Ku, Sheng-Yu http://orcid.org/0000-0003-4715-1888
Venkadakrishnan, Varadha Balaji http://orcid.org/0000-0001-7071-4584
Korsen, Joshua A.
Kalidindi, Teja M.
Mizuno, Kei
Ahn, Shin Hye http://orcid.org/0000-0003-4700-4861
Seo, Ji-Heui
Garcia, Maria Mica
Khani, Francesca http://orcid.org/0000-0001-7238-8604
Elemento, Olivier http://orcid.org/0000-0002-8061-9617
Long, Henry W. http://orcid.org/0000-0001-6849-6629
Chaglassian, Alain
Pillarsetty, Nagavarakishore http://orcid.org/0000-0002-1750-7436
Lewis, Jason S. http://orcid.org/0000-0001-7065-4534
Freedman, Matthew http://orcid.org/0000-0002-0151-1238
Belanger, Anthony P.
Nguyen, Quang-De
Beltran, Himisha http://orcid.org/0000-0003-3259-2226
-
Funding
Funding for this research was provided by:
U.S. Department of Defense (W81XWH-22-1-0010, W81XWH-17-1-0653)
U.S. Department of Health & Human Services | NIH | National Cancer Institute (R37CA241486)
Prostate Cancer Foundation
- License Information
-
More Information
Article History
Received: 24 July 2022
Accepted: 6 March 2023
First Online: 10 April 2023
Change Date: 22 May 2023
Change Type: Update
Change Details: In the version of this article initially published, the citation to Figure 6i originally cited Figure 5i, while the panel label for Figure 5h appeared originally as 5f; the errors have been corrected in the HTML and PDF versions of the article.
Competing interests
: H.B. participated in a virtual advisory board meeting with Blue Earth Diagnostics in 2021. A.C. is employed by Blue Earth Diagnostics. Blue Earth Diagnostics provided tracer for this study but had no role in study design, data collection and analysis, decision to publish or preparation of the manuscript. H.B. has also served as consultant/advisory board member for Janssen, Astellas, AstraZeneca, Merck, Pfizer, Foundation Medicine, Amgen, Bayer, Oncorus, LOXO, Daicchi Sankyo and Curie Therapeutics and has received research funding (to institution) from Janssen, AbbVie/Stemcentrx, Eli Lilly, Astellas, Millennium, Bristol Myers Squibb, Circle Pharma and Daicchi Sankyo. O.E. is supported by Janssen, J&J, AstraZeneca, Volastra and Eli Lilly research grants. He is scientific advisor and equity holder in Freenome, Owkin, Volastra Therapeutics, Pionyr Immunotherapeutics, Harmonic and One Three Biotech and a paid scientific advisor to Champions Oncology. All other authors have no competing interests.
